<DOC>
	<DOCNO>NCT00953147</DOCNO>
	<brief_summary>This 6-month multi-center , randomize , double-blind , placebo-controlled , parallel group , efficacy safety study ciclesonide HFA nasal aerosol administer once-daily male female subject 12 year old diagnose perennial allergic rhinitis ( PAR ) .</brief_summary>
	<brief_title>A 6 Month Safety Efficacy Study Once Daily Ciclesonide Hydrofluoroalkane ( HFA ) Treatment Perennial Allergic Rhinitis ( PAR ) Subjects 12 Years Older</brief_title>
	<detailed_description>This study investigate efficacy safety daily ciclesonide HFA Nasal Aerosol 26 week . The primary objective evaluate efficacy ciclesonide HFA ( 80 mcg 160 mcg ) 6 week , compare placebo subject PAR . Secondary objective evaluate safety tolerability quality life treatment ciclesonide HFA ( 80 mcg 160 mcg ) , 6 week 6 month . The study consist Screening period ( 7 21 ( ±3 ) day ) Visit 1 Visit 2 , follow Single-blind Placebo Run-in period ( 7 10 day ) Visit 2 Visit 3 , follow 6-month ( 26 week ) double-blind treatment period ( Visit 3 Visit 11 ) . Subjects complete study allow participate 6-month open-label extension study ( Study 060-635 ) . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Give write informed consent assent , include privacy authorization well adherence concomitant medication withhold period , prior participation . Subject must general good health base screen physical examination , medical history , clinical laboratory value . If Screening visit Hematology , Chemistries , Urinalysis within clinical laboratory 's reference range , subject include Investigator judge deviation clinically significant . A history PAR relevant perennial allergen ( house dust mite , cockroach , mold , animal dander ) minimum two year immediately precede study Screening visit . The PAR must sufficient severity require treatment ( either continuous intermittent ) past require treatment throughout entire study period . A demonstrated sensitivity Screening visit least one allergen know induce PAR ( house dust mite , animal dander , cockroach , mold ) use standard skinprick test . The subject 's positive allergen test must consistent medical history PAR must present subject 's environment throughout study . Based upon subject 's medical history , Investigator 's judgment , subject unlikely seasonal exacerbation first 6 week doubleblind treatment . Subject , female ≤65 year age , must negative serum pregnancy test screening . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control . Female subject pregnant lactating . History physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation ; recent nasal biopsy ; nasal trauma ; nasal ulcer perforation . Surgery atrophic rhinitis rhinitis medicamentosa permit within last 60 day prior Screening visit . Subject , investigator 's judgement , seasonal exacerbation time screen . Participation investigational drug trial within 30 day precede Screening visit plan participation another investigational drug trial time trial . A known hypersensitivity corticosteroid excipients formulation ciclesonide . History respiratory infection disorder [ include , limited bronchitis , pneumonia , influenza , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening visit . History alcohol drug abuse within 2 year precede Screening visit . History positive test HIV , hepatitis B hepatitis C. Active asthma require treatment inhale systemic corticosteroid and/or routine use beta agonist controller drug ( eg , theophylline , leukotriene antagonist , etc . ) ; intermittent use ( less equal 3 us per week ) inhale short act betaagonists acceptable . Use short act betaagonists exerciseinduced bronchospasm allow . Expected use disallow concomitant medication treatment period . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit use stable ( maintenance ) dose ( 30 day ) may consider inclusion . Previous participation intranasal ciclesonide HFA nasal aerosol study . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit . Initiation pimecrolimus cream 1 % great tacrolimus ointment 0.03 % great study period plan dose escalation study period . Study participation clinical investigator site employee and/or immediate relative reside household . Study participation one subject household . Have follow condition judge investigator clinically significant and/or affect subject 's ability participate clinical trial : impaired hepatic function include alcohol relate liver disease cirrhosis history ocular disturbance , eg , glaucoma posterior subcapsular cataract systemic infection hematological , hepatic , renal , endocrine ( except control diabetes mellitus postmenopausal symptom hypothyroidism ) gastrointestinal disease malignancy ( exclude basal cell carcinoma ) current neuropsychological condition without drug therapy • Any condition , judgment investigator , would preclude subject complete protocol capture assessment write .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>